Granulocyte colony-stimulating factor as a cause of acute leucocytoclastic vasculitis with anti-Ro and anti-La antibodies

BMJ Case Rep. 2022 Apr 22;15(4):e249311. doi: 10.1136/bcr-2022-249311.

Abstract

Granulocyte colony-stimulating factor (G-CSF) administration is associated with a diverse range of cutaneous sequelae. Serious dermatological side effects of G-CSF include the development of Sweet's syndrome and exacerbations of pre-existing inflammatory disorders such as psoriasis. Here, we describe a report of acute leucocytoclastic vasculitis caused by G-CSF therapy associated with anti-Ro and anti-La antibodies in a patient with multiple myeloma. This case highlights the importance of having a high index of suspicion for acute leucocytoclastic vasculitis in patients with haematological malignancies undergoing G-CSF therapy.

Keywords: Contraindications and precautions; Dermatology; Immunology; Malignant and Benign haematology; Oncology.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Antinuclear
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Humans
  • Skin / pathology
  • Sweet Syndrome* / drug therapy
  • Vasculitis, Leukocytoclastic, Cutaneous* / chemically induced
  • Vasculitis, Leukocytoclastic, Cutaneous* / complications
  • Vasculitis, Leukocytoclastic, Cutaneous* / drug therapy

Substances

  • Antibodies, Antinuclear
  • Granulocyte Colony-Stimulating Factor

Supplementary concepts

  • Erythema elevatum diutinum